|
Allakos Inc. is a clinical stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. It is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It also developed a formulation of lirentelimab for subcutaneous (SC) administration. The Company is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.
Number of employees : 192 people.
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
Stock A |
1 |
85,203,597 |
81,532,017 |
95.7% |
0 |
0.0% |
95.7% |
|
|
Name | Equities | % | Alta Partners Management Corp. | 9,050,493 |
10.6% | Capital Research & Management Co. (World Investors) | 6,614,358 |
7.76% | NEA Management Co. LLC | 6,148,704 |
7.22% | Logos Global Management LP | 5,936,666 |
6.97% | BVF Partners LP | 5,006,921 |
5.88% | Capital Research & Management Co. (Global Investors) | 4,912,458 |
5.77% | RiverVest Venture Management LLC | 4,887,932 |
5.74% | Frazier Life Sciences Management LP | 4,792,000 |
5.62% | Deep Track Capital LP | 4,518,575 |
5.30% | Vivo Capital LLC | 4,120,134 |
4.84% |
|
|
|
Sector Bio Therapeutic Drugs
| | 1st jan. | Capi. (M$) |
 | ALLAKOS INC. | -18.29% | 586 |
| | | |
 | REGENERON PHARMACEUTICALS, INC. | 3.90% | 80 008 |
 | VERTEX PHARMACEUTICALS | 1.58% | 75 386 |
 | WUXI APPTEC CO., LTD. | 12.01% | 39 187 |
 | BIONTECH SE | -6.04% | 34 302 |
 | BEIGENE, LTD. | 13.65% | 26 029 |
 | GENMAB A/S | -8.09% | 25 460 |
 | ARGENX SE | 0.98% | 20 922 |
 | SAREPTA THERAPEUTICS, INC. | -6.34% | 10 653 |
 | NEUROCRINE BIOSCIENCES, INC. | -12.52% | 10 045 |
 | LEGEND BIOTECH CORPORATION | -1.54% | 8 228 |
 | HALOZYME THERAPEUTICS, INC. | -11.56% | 6 804 |
 | KARUNA THERAPEUTICS, INC. | -0.41% | 6 662 |
 | ASCENDIS PHARMA A/S | -6.18% | 6 416 |
 | REMEGEN CO., LTD. | 8.81% | 6 107 |
 | EXELIXIS, INC. | 10.72% | 5 756 |
 | PHARMAESSENTIA CORPORATION | 7.13% | 5 123 |
 | CEREVEL THERAPEUTICS HOLDINGS, INC. | 2.92% | 5 072 |
 | AKESO, INC. | 9.19% | 5 030 |
 | MADRIGAL PHARMACEUTICALS, INC. | -10.45% | 4 638 |
 | INTRA-CELLULAR THERAPIES, INC. | -10.68% | 4 580 |
Connections : Allakos Inc.
|